Type 1 Diabetes Vaccine Shows Promise in Early Study

Drug & Device Development
Last Updated: 2013-06-26 17:00:28 -0400 (Reuters Health)
By Julie Steenhuysen

CHICAGO (Reuters) - An early stage study suggests an experimental DNA vaccine may be able to tame bits of the immune system that go haywire in people with type 1 diabetes, offering hope for a new way to delay or prevent the autoimmune disease, researchers said on Wednesday.

For more than four decades, scientists have tried different ways of manipulating the immune system to stop the destruction of insulin-producing beta cells that is responsible for type 1 diabetes. The disease affects as many as 3 million Americans.

Some prior attempts suppressed desirable parts of the immune system, leaving individuals vulnerable to infections and cancer. Several teams are now attempting more targeted approaches in an effort to delay or reverse type 1 diabetes.

"What one really wants to do is tame or regulate the specific aspects of the immune system that have gone awry and leave the rest of the immune system intact," said Dr. Richard Insel, chief scientific officer of JDRF, formerly known as the Juvenile Diabetes Research Foundation.

In the latest effort, published on Wednesday in the journal Science Translational Medicine, teams from Leiden University Medical Center in the Netherlands and Stanford University in California tested a vaccine genetically engineered to shut down only the immune system cells causing harm, while leaving the rest of the immune system intact.

"The idea here is to turn off just the rogue immune cells that are attacking the pancreas and killing the beta cells that secrete insulin," said Stanford Professor Dr. Lawrence Steinman, one of the study's senior authors and co-founder of a company called Tolerion recently formed to commercialize the vaccine.

The study, done in 80 people diagnosed with type 1 diabetes who were receiving insulin injections, was designed to test the safety of the vaccine known as TOL-3021. The DNA vaccine is made up of a plasmid that is genetically engineered to tamp down the immune response to insulin and preserve insulin-producing beta cells.

The vaccine targets a precursor protein in the blood called proinsulin. "It's a complicated series of snips and cuts in the DNA that take away the capability to stimulate the immune system," Steinman said.

"This effectively triggers an off-switch," he said.

After 12 weeks of shots given once a week, patients who got the vaccine showed signs that it helped preserve some of the remaining insulin-producing beta cells in the pancreas without causing serious side effects.

The vaccine also reduced the number of CD8+ T cells. And patients who got the active vaccine had higher levels of C-peptide - a remnant of insulin production in the blood that suggests the presence of more working beta cells.

With this study, say the researchers, "we demonstrate that a plasmid encoding proinsulin reduces the frequency of CD8+ T cells reactive to proinsulin while preserving C-peptide over the course of dosing."

Steinman admits the vaccine is far from commercial use, but the study is promising enough to do a bigger study.

"So far, it looks like it is doing what we want," he said.

Insel said it was too early to say much about the vaccine's promise. "It looks like it has some potential, but very small numbers," he said.

"This was done initially as a safety and dose-finding study. They were surprised to get these kinds of results," he said.

Stanford has licensed rights to the vaccine to California-based Tolerion, which is designing a longer study in as many as 200 patients to test whether the vaccine can slow or stop progression of the disease in younger patients, before too much damage has been done.

Insel said the work is one of several efforts aimed at developing a vaccine for type 1 diabetes. Such a vaccine could help people with active type 1 diabetes preserve residual beta cells, giving them better control of their disease and potentially getting them off insulin.

Ultimately, the hope is to develop an effective vaccine that could be given to individuals who are genetically predisposed to develop the condition, he said.

SOURCE: http://bit.ly/14xfFaG

Sci Transl Med 2013.

Copyright © 2013 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.